Irked by a pharma CEO's broken promise? We're making a list

FiercePharma is compiling a list of the biggest broken promises by pharma executives in recent years. (Shutterstock/Deviney Designs)

Biotech and pharma CEOs are used to having their words recorded. Whether it's at an investor conference, an industry confab, a press conference or a quarterly earnings call, CEO statements end up everywhere from webcasts to reporters' notebooks.

Sometimes, those statements aren't just facts. They're pledges of one kind or another. And while executives often hold true to their public statements, sometimes they just don't.

This fall, we’re planning to highlight the biggest promises made and broken by biopharma execs in recent years—and we’re turning to readers to help compile the list. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Be it a promise not to raise prices or settle a lawsuit, a promise to hit a particular long-term sales target, a promise not to sell a company, unforeseen layoffs, misleading M&A comments or more, we want to hear your ideas for the upcoming feature. Anytime a pharma CEO said one thing and did another, that’s worth noting. 

We’ll plan to highlight a group of the broken promises in a special report this October. Please share your ideas in this form. Nominations are open until Aug. 30. Questions in the meantime? Feel free to get in touch through email or Twitter.

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.